Price T Rowe Associates Inc Allogene Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,177,619 shares of ALLO stock, worth $9.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,177,619

Previous 2,371,472 76.16%

Holding current value

$9.73 Million

Previous $7.61 Million 145.3%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $5.27 Million - $10.2 Million	1,806,147 Added 76.16%	4,177,619 $18.7 Million
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $81,795 - $125,562	-35,875 Reduced 1.49%	2,371,472 $7.61 Million
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $9.27 Million - $17.4 Million	-2,924,053 Reduced 54.85%	2,407,347 $7.63 Million
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $4.53 Million - $6.73 Million	-998,904 Reduced 15.78%	5,331,400 $26.5 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $1.91 Million - $3.19 Million	388,507 Added 6.54%	6,330,304 $31.3 Million

Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $193,783 - $383,083	34,481 Added 0.58%	5,941,797 $37.4 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $3.59 Million - $6.02 Million	348,140 Added 6.26%	5,907,316 $63.8 Million
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $8.76 Million - $15.9 Million	1,292,441 Added 30.29%	5,559,176 $63.4 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $7.77 Million - $15.5 Million	1,015,207 Added 31.22%	4,266,735 $38.9 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $14.3 Million - $26.7 Million	-1,087,463 Reduced 25.06%	3,251,528 $48.5 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $16.9 Million - $22.2 Million	803,807 Added 22.74%	4,338,991 $112 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $1.84 Million - $2.81 Million	78,431 Added 2.27%	3,535,184 $92.2 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $2.66 Million - $4.02 Million	-103,040 Reduced 2.89%	3,456,753 $122 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $89.8 Million - $155 Million	3,559,793 New	3,559,793 $89.8 Million

Others Institutions Holding ALLO

# of Institutions

164

Shares Held

106M

Call Options Held

97.5K

Put Options Held

45.6K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $335M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Allogene Therapeutics, Inc. Transaction History